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Abstract 
There has been an increasing trend in the number of prescribed and over-the-counter drug recall 
over the last few years. The recall is usually due to company's discovery, customer's complaint or 
Food and Drug Administration (FDA) observation. The process of recall involves a planned 
specific course of action, which addresses the depth of recall, need for public warning, and the 
extent of effectiveness checks for the recall. The FDA review and/or recommend changes to the 
firm's recall strategy, as appropriate. The critical recall information list includes the identity of 
the product; summary of the failure; amount of product produced in the distribution chain and 
direct account. Product recalls clashes thousands of companies every year affecting: sales, testing 
customer relationships and disrupting supply chains. Drug recall is incubus for pharmaceutical 
companies. It effects the reputation of the company. The reason for the recall can be divided into 
two categories: manufacturing related and safety/efficacy related. It is essential to follow all the 
guidelines related to drug development and manufacturing procedure so as to minimize drug 
recall. 
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INTRODUCTION 
The pharmaceutical industry is at an important crossroads in medical innovations, which develop 
cures for health conditions. Without this industry, many therapies would not be introduced to the 
market, and many health problems would remain unsolved. The pharmaceutical industry as a 
whole has traditionally been very profitable, and the global market had annual growth prediction 
of 5 to 8% 
1, 2
.  Yet amidst the massive increase in the field, factors like product returns and 
recalls are giving the companies new challenges, such as litigation problems, negative publicity, 
loss of patent protection for many major drugs and widespread efforts to contain drug spending
3
.
 
On the other hand, increased competitiveness, fast-changing structure of competitors, complex 
strategic positioning, shrinking pipelines, counterfeit drugs and a fight for global market share 
are adding more burdens to the growth of the industry 
4, 5
. 
A recall is a serious problem. It highlights a dangerous situation that requires fast and effective 
action to protect the public from harm. Product recalls are becoming extensive and have 
increased radically 
6
. For example, the Food and Drug Administration (FDA) reported more than 
1984 recalls with more than $700 million dollars manufacturers penalties, and billions more in 
lost revenues since 2001 
7,8
. Companies are turning to set their strategic sight on future moves. In 
order to operate effectively in an increasingly competitive economic and commercial landscape, 
they are trying to adopt more formal business processes and stricter reporting methods 
9
. 
A drug recall is an instance to return to the maker a batch or an entire production run of a drug 
product, usually due to the detection of safety issues or drug product defect. When drug products 
are known to have potentially harmful effect on users due to their defective quality, safety or 
efficacy, they may be subjected to a recall and all related information's are reported to the drug 
office 
10
.  Regardless of a company's best efforts, that dangerously defective drug product may 
reach the customers. These products may cause disasters, leading to adverse verdicts in drug 
product liability litigations. The quality management of complaints and drug product recalls are 
necessary to ensure the safety of customer. However, there are certain other cases when all 
batches or lots of the drug experience recall from the market 
11, 12
. The aim of present review is 
to focus on issues for drug recall like lack of sterility assurance, presence of particulate matter, 
unapproved new drugs, presence of undeclared therapeutically active moiety, microbial 
 contamination, container/closure problems and some other miscellaneous reasons. We shall 
discuss them in two parts with part-I, focusing on lack of sterility assurance, presence of 
particulate matter and container/closure problems. 
ISSUES RELATED TO PRODUCT RECALL 
I- Lack of Sterility Assurance 
The years 2013-2016 saw eight recalls (Table 1) that involved a microbiological component, 
with a clear increase evident in 2015 and 2016. There no evident in 2013 and 2014. If we look at 
the data from a different perspective, we can evaluate FDA concerns for sterile vs Non-sterile 
products 
13, 14
. Underlying causes of “Lack of Sterility Assurance” often are the result of 
packaging concerns (incomplete or weak seals, pinpricks in the sterile barrier, transport issues, 
etc). Relatively few of these “Lack of Sterility Assurance” recalls actually showed 
contamination. From this, it seems apparent that “Lack of Sterility Assurance” means either that 
there is a potential problem with the product or packages, or that the manufacturer cannot 
document that the product was manufactured and sterilized in a state of control. If the product is 
obviously contaminated, that is the cited reason for the recall in the vast majority of cases 
15, 16
.
  
Table 1: Lack of sterility assurance 
S.No Date Product Description Reasons/ Problems Company 
1. 17/05/2016 Unexpired sterile 
compounded products 
Concern over lack of sterility 
assurance 
Well Care Compounding 
Pharmacy 
2. 19/04/2016 Sterile compounded products Lack of sterility assurance Pharmakon Pharmaceuticals, 
Inc. 
3. 16/01/2016 Sterile Compounded 
Products that include 
injectable medications, sterile 
solutions, eye drops, and eye 
ointments 
Lack of sterility assurance Abbott's Compounding 
Pharmacy 
4. 20/10/2015 All sterile compounded 
products 
Lack of sterility assurance Company Name Downing 
Labs, LLC 
5. 21/09/2015 All sterile compounded 
products 
Lack of sterility assurance US Compounding, Inc. 
6. 09/09/2015 Sterile drug products Sterility cannot be assured Medistat RX, LLC 
7. 17/08/2015 
 
Prolotherapy with Phenol Non-sterility concerns Hartley Medical 
8. 07/08/2015 Human and veterinary sterile 
compounded drugs 
Sterility Assurance Moses Lake Professional 
Pharmacy 
 
II- Presence of Particulate Matter 
Presence of foreign visible or sub-visible particulate matter in injectable/ parenteral formulations 
has been one of the most commonly seen reasons for recalls. FDA reported 22 % recalls for 
sterile injectable drugs in period of 2013-16 caused due to presence of visible particles 
17, 18
. 
Recent list of FDA recalls include the products as mentioned in the (Table 2).  All injectables are 
mostly contaminated with some level of particulate matter. This particulate matter is a critical 
quality attribute, which has direct impact on product safety. Therefore, the United States 
Pharmacopoeia has defined the standards for particulate matter. These standards are established 
for all injectable preparations such as large-volume Injections, single-dose infusion and small-
volume Injections, solutions for injection administered by intramuscular or subcutaneous route, 
except parenterals for use as irrigating solutions, radiopharmaceutical preparations and parenteral 
products for which the labeling specifies use of a final filter prior to administration 
19,20
. 
The size of particulate matter is an important factor behind health risk to patients. The smallest 
diameter of blood capillaries is approximately 6–8 μm. Particles as small as 2 μm in diameter are 
 generally associated with micro-thrombi formation in patients. Particles larger than 6–8 µm can 
block pulmonary capillaries, with smaller particles passing through the lungs and depositing in 
organs such as the liver and spleen, where they are processed by phagocytic cells of the 
reticuloendothelial system 
21, 22
.  
Table 2: Presence of particulate matter 
S.No Date Product Description Reasons/ Problems Company 
1. 05/05/2016 
 
Sterile Preparations Compounded With Fresenius 
Kabi Sensorcaine-MPF (bupivacaine HCl) 
Presence of glass particulate PharMEDium Services 
LLC 
2. 13/04/2016 50%  magnesium sulfate Injection, USP Particulate Matter Hospira, Inc. 
3. 28/03/2016 
 
5% dextrose Injection USP Leakage and visible particulate 
matter (microbial growth) 
B. Braun Medical Inc. 
4. 1803/2016 8.4% sodium bicarbonate Injection, USP Presence of particulate matter Hospira Inc. 
5. 09/03/2016 amikacin  sulfate Injection USP, 1 gram/4mL (250 
mg/mL) 
Due to the potential presence of 
particulate matter identified as 
glass in one vial 
Teva Pharmaceuticals 
6. 17/02/2016 0.9% sodium chloride Solution Particulate Matter Baxter International Inc. 
8. 18/12/2015 intravenous (IV) solutions: 0.9% sodium chloride 
Injection, USP, 250 mL VIAFLEX Plastic Container 
and 70% dextrose injection (2000 mL) USP 
Potential presence of particulate 
matter 
Baxter International Inc. 
9. 24/08/2015 REFRESH® Lacri-Lube®, REFRESH P.M.®, 
FML® (fluorometholone ophthalmic ointment) and 
Blephamide® (sulfacetamide sodium and 
prednisolone acetate ophthalmic ointment, USP) 
Contains particulate matter Allergan plc 
10. 31/07/2015 0.9 % sodium chloride Injection, USP (AUTO-C) Leaking containers, particulate 
matter and missing port protectors 
Baxter International Inc. 
11. 24/07/2015 Adrucil (fluorouracil injection, USP) 5 g/100 mL (50 
mg/mL) 
Potential presence of particulate 
matter 
Teva Parenteral 
Medicines Inc. 
12. 17/07/2015 0.9 % Sodium Chloride Injection, USP; 50mL and 
100 mL 
Presence of particulate matter Baxter International Inc. 
13. 08/06/2015 
 
gemcitabine, methotrexate Particulate Matter Mylan 
14 23/12/2013 lidocaine HCl Injection Particulate matter Hospira, Inc 
15. 23/12/2013 5 percent dextrose Injection, USP and 0.9 percent 
sodium chloride Injection, USP 
Particulate matter Baxter International Inc 
16. 13/12/2013 Soliris (eculizumab) 300 mg/30 mL Concentrated 
solution for intravenous infusion only 
Found to contain visible particles Alexion 
Pharmaceuticals, Inc. 
17. 27/11/2013 nitroglycerin in 5% dextrose Injection Particulates matter Baxter International Inc. 
III- Container/Closure Problems 
Leaking containers could result in contamination of the solution. If not detected, this could lead 
to a bloodstream infection, worsened patient condition or other serious adverse health 
consequences (Table 3). All medicinal products need to be protected and consequently need to 
be packaged in containers that conform to prescribed standards, particularly with respect to the 
exclusion of moisture and light and the prevention of leaching of extractable substances into the 
contents and of chemical interaction with the contents. However, the limits of acceptability in 
these various respects depend, at least in part, on climatic variables. Recommendations in the 
International Pharmacopoeia can only be advisory; precise quantitative standards will have to be 
locally determined.
 
Labels carry the correct information and identification of the product 
23, 24
.
 
The closure is a part of the container. The container and its closure must not interact physically 
or chemically with the substance within in any way that would alter its quality 
25, 26
. Both the 
 European and United States pharmacopoeias provide specifications for glass containers for 
injections. 
27
 The latter publication also gives specific guidance for the packaging, repackaging 
and dispensing of medicinal products. Both the European and United States pharmacopoeias also 
provide specifications for light-resistant containers and tightly or well-closed closures for 
capsules and tablets 
28
.  
Table 3: Container/Closure problems 
S.No Date Product Description Reasons/ Problems Company 
1. 28/03/2016 
 
5% dextrose Injection USP Leakage and visible particulate 
matter (microbial growth) 
B. Braun Medical Inc. 
2. 26/01/2016 0.9% sodium chloride Injection, 
metronidazole Injection, and 
clinimix  
Leaking containers and 
particulate matter 
Baxter International 
Inc. 
3. 31/07/2015 0.9 % sodium chloride Injection, 
USP (AUTO-C) 
Leaking containers, particulate 
matter and missing port 
protectors 
Baxter International 
Inc. 
 
 
CONCLUSION 
Product Recall is not only a blot on the company’s image but also an unwanted procedure on part 
of manufacturers. However, in the interest of patients in particular and society in general, this is 
a welcome step. The manufacturers should check everything before releasing the product in 
market. In spite of frequent in process quality controls, QC tests past production and cGMPs in 
place, there has been an alarming rise in the incidences of product recall. Keeping in mind 
stringest FDA regulations, such an event speaks volumes about the lacunas in the existing 
system. Therefore, even after launch of the drug in the market, it is essential to carry out post 
market surveillance and investigate the drug performance in the market. 
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